Johnson & Johnson eyes up to $3.4bn Ollin Biosciences deal
Biotechnology dealmaking remains elevated this year as large drugmakers keep pursuing targeted acquisitions to expand their pipelines. Johnson & Johnson is poised to buy eye disease developer Ollin Biosciences for up to $3.4 billion, a move that would broaden its reach in retinal medicines.
Highlights
- Johnson & Johnson is negotiating a potential acquisition of Ollin Biosciences for up to $3.4 billion, including $2.2 billion upfront and $1.2 billion in milestone payments.
- The acquisition would grant J&J entry into the retinal disease treatment market, leveraging Ollin's OLN324 drug set for late-stage trials in wet AMD and diabetic macular oedema.
- Biotech M&A remains robust with 46 $1 billion-plus deals totaling $131.5 billion in the first half of 2024, although activity has slowed to $44.8 billion in the second half.
Deal terms and strategic fit
As first reported by the Financial Times, Johnson & Johnson could announce an acquisition of privately held Ollin Biosciences as soon as Monday, according to people familiar with the matter.The terms under discussion include $2.2 billion in upfront cash and another $1.2 billion tied to potential milestone payments, although the people cautioned that the talks could still collapse. J&J declined to comment, while Ollin did not respond to requests for comment.
Ollin, backed by Arch Venture Partners and Mubadala Capital, is developing a medicine for two major causes of severe vision loss later in life. Its lead drug, OLN324, is set to enter late-stage trials for wet age-related macular degeneration and diabetic macular oedema, both of which can cause serious vision impairment.
An acquisition would give J&J a foothold in retinal disease treatments, an area where it has limited presence despite its large contact lens business. The company has already been active on acquisitions, agreeing a $1 billion deal for oncology developer Firefly Bio earlier this year and a $14.6 billion takeover of Intra-Cellular Therapies at the start of last year.
Biotech M&A momentum stays strong
The potential transaction comes as the pharmaceutical industry prepares to gather in London for the Jefferies healthcare summit this week, a key event for executives, investors and advisers. It also arrives during a record year for biotech sales, with 46 biotechs valued at more than $1 billion sold so far this year, surpassing the previous annual record of 35, according to Stifel.After a strong first half, when $131.5 billion of biotech deals were agreed, activity has slowed in recent months. Transactions in the second half of the year total $44.8 billion so far.
Large pharmaceutical groups have continued to pursue eye disease assets in recent years, with companies including Merck and Bayer acquiring earlier-stage businesses. Regeneron's retinal treatment Eylea has been one of the sector's most successful blockbuster medicines, underscoring the commercial potential of the market.
Ollin raised $330 million earlier this year to fund its upcoming phase-three trials. Its backers also include TCGX, RA Capital and Monograph Capital, while J&J shares are up 38 per cent so far this year, giving the company a market capitalisation of nearly $688 billion at Friday's close.
In earlier coverage, we examined Canaccord’s UK wealth sale to Centerbridge and Mubadala for about £564 million.